upper
respiratori
tract
viral
infect
one
common
acut
respiratori
ill
experienc
human
healthi
individu
infect
usual
selflimit
associ
rel
mild
symptom
clinic
syndrom
refer
common
cold
accord
center
diseas
control
prevent
cold
result
million
lost
school
day
year
unit
state
alon
moreov
american
experi
million
upper
respiratori
tract
viral
infect
per
year
exclud
infect
due
influenza
lead
total
annual
econom
impact
estim
billion
fendrick
et
al
number
differ
viral
type
includ
coronavirus
respiratori
syncyti
viru
rsv
parainfluenza
virus
induc
upper
respiratori
symptom
half
cold
caus
human
rhinoviru
hrv
infect
arruda
et
al
makela
et
al
although
healthi
individu
experi
simpl
common
cold
rel
small
percentag
case
develop
complic
includ
acut
sinus
otiti
media
arola
et
al
turner
et
al
gwaltney
et
al
seriou
complic
howev
occur
subject
preexist
lower
airway
diseas
asthma
chronic
obstruct
pulmonari
diseas
copd
cystic
fibrosi
cf
upper
respiratori
viru
infect
major
trigger
acut
diseas
exacerb
lifethreaten
major
caus
emerg
room
visit
hospit
moreov
consider
evid
viru
induc
wheez
ill
earli
childhood
major
risk
factor
subsequ
develop
asthma
latter
observ
also
prompt
investig
whether
respiratori
viral
infect
may
also
contribut
develop
structur
chang
refer
airway
remodel
occur
airway
subject
asthma
fact
sever
virus
abl
exacerb
lower
airway
diseas
suggest
common
mechan
underli
pathophysiolog
effect
recent
new
insight
gain
pathway
mediat
effect
virus
lower
airway
diseas
review
place
particular
emphasi
compon
pathway
may
provid
possibl
new
target
therapeut
intervent
discuss
new
therapeut
approach
clearli
requir
current
avail
medic
treatment
lower
airway
diseas
less
optim
treatment
viral
exacerb
lower
airway
diseas
moreov
none
current
treatment
option
prevent
develop
airway
remodel
asthma
revers
exist
featur
remodel
respiratori
viral
infect
major
trigger
episod
wheez
children
although
number
viru
type
includ
parainfluenza
metapneumoviru
influenza
trigger
bronchiol
wheez
heymann
et
al
jartti
et
al
william
et
al
initi
studi
focus
rsv
major
caus
bronchiol
young
infant
particularli
winter
month
studi
show
children
develop
rsv
induc
bronchiol
earli
childhood
impair
lung
function
later
life
strope
et
al
children
also
increas
risk
recurr
wheez
develop
asthma
age
stein
et
al
sigur
et
al
although
data
tucson
children
respiratori
studi
show
risk
decreas
progress
age
longer
signific
age
stein
et
al
studi
indic
rsv
bronchiol
sever
enough
caus
hospit
infanc
still
risk
factor
asthma
adolesc
sigur
et
al
studi
focus
rsv
improv
sensit
viral
detect
result
introduct
revers
transcriptionpolymeras
chain
reaction
rtpcr
gener
strong
evid
much
greater
role
hrvinduc
wheez
ill
infanc
major
risk
factor
subsequ
develop
asthma
previous
appreci
outsid
winter
month
children
older
month
age
hrv
appear
domin
viral
pathogen
associ
wheez
ill
heymann
et
al
jartti
et
al
korppi
et
al
report
children
hospit
hrvinduc
bronchiol
particularli
high
risk
subsequ
develop
asthma
reijonen
et
al
et
al
addit
seri
public
high
risk
childhood
origin
asthma
coast
birth
cohort
studi
show
hrv
induc
wheez
ill
first
year
life
strongest
predictor
subsequ
wheez
third
year
life
also
children
wheez
third
year
life
confirm
asthma
age
jackson
et
al
interestingli
studi
children
wheez
rhinovirusassoci
ill
significantli
higher
risk
develop
chronic
wheez
asthma
wheez
due
ill
associ
rsv
moreov
clear
evid
children
experi
recurr
respiratori
ill
due
serial
hrv
infect
jartti
et
al
although
virus
induc
wheez
ill
children
predispos
develop
asthma
children
experi
rsv
infect
age
children
experi
repeat
hrv
infect
render
subset
children
suscept
develop
wheezi
bronchiol
subsequ
asthma
yet
entir
clear
undoubtedli
genet
compon
asthma
suscept
genom
wide
associ
studi
identifi
multipl
candid
genesloci
link
asthma
ober
yao
clear
howev
underli
genet
suscept
complex
herit
account
littl
diseas
accord
estim
ober
yao
thu
seem
like
addit
environment
factor
play
role
determin
suscept
asthma
develop
led
paradigm
twohit
conceiv
multiplehit
thesi
develop
asthma
recurr
viral
infect
set
addit
risk
factor
may
necessari
trigger
subsequ
develop
asthma
relev
factor
earli
childhood
could
contribut
regul
suscept
develop
asthma
includ
impair
lung
develop
reduc
lung
function
martinez
et
al
gern
et
al
live
farm
von
mutiu
vercelli
cigarett
smoke
exposur
gilliland
et
al
daycar
attend
earli
life
nystad
breastfeed
gdalevich
et
al
antibiot
use
kozyrskyj
et
al
allerg
sensit
rake
et
al
although
concept
two
independ
risk
factor
may
interact
induc
develop
asthma
attract
limit
understand
import
rel
time
durat
exposur
regul
asthma
suscept
case
allerg
sensit
viralinduc
wheez
recogn
independ
risk
factor
asthma
develop
jackson
et
al
recent
studi
examin
tempor
relationship
risk
factor
coast
studi
birth
cohort
jackson
et
al
markov
model
data
indic
allerg
sensit
increas
risk
develop
hrvinduc
wheez
alter
risk
rsvinduc
wheez
contrast
viral
wheez
lead
increas
risk
subsequ
allerg
sensit
data
could
interpret
suggest
allerg
sensit
must
preced
viral
wheez
develop
asthma
note
caution
warrant
first
studi
cohort
highrisk
popul
select
least
one
parent
document
respiratori
allergi
thu
may
fulli
repres
broader
popul
second
patient
sensit
allergen
year
age
approxim
children
alreadi
experienc
wheez
episod
time
impli
viral
wheez
ill
necessarili
requir
prior
allergen
sensit
may
viru
specif
reflect
preval
rsv
earli
month
clear
final
impact
potenti
risk
factor
list
examin
thu
data
intrigu
addit
studi
need
examin
tempor
relationship
viralinduc
wheez
episod
risk
factor
lead
subsequ
develop
asthma
lower
airway
individu
asthma
show
seri
structur
chang
characterist
diseas
collect
refer
airway
remodel
chang
includ
increas
mass
smooth
muscl
angiogenesi
thicken
lamina
reticulari
increas
number
myofibroblast
enhanc
matrix
protein
deposit
thicken
fragil
epithelium
well
goblet
cell
metaplasia
accompani
excess
mucu
product
jefferi
togeth
chang
increas
thick
airway
wall
narrow
airway
lumen
sobonya
laitinen
et
al
jefferi
et
al
siddiqui
et
al
believ
underli
develop
persist
airway
hyperrespons
hallmark
asthma
mcparland
et
al
jame
wenzel
et
al
although
asthma
occur
age
usual
alreadi
evid
childhood
major
patient
gern
et
al
sear
et
al
despit
longstand
paradigm
held
airway
remodel
occur
year
chronic
airway
inflamm
number
bronchial
biopsi
studi
conduct
children
howev
clearli
establish
airway
remodel
present
infant
month
old
symptom
airflow
limit
saglani
et
al
sever
major
compon
remodel
alreadi
present
preschool
children
symptom
airflow
limit
even
formal
clinic
diagnosi
asthma
made
pohunek
et
al
saglani
et
al
oreilli
et
al
absenc
airway
remodel
infant
presenc
preschool
children
rais
prospect
remodel
induc
consequ
initi
stimuli
experienc
earli
childhood
remodel
occur
parallel
airway
inflamm
consid
potenti
stimuli
could
contribut
initi
progress
remodel
suscept
individu
hrv
infect
consid
note
hrv
induc
wheez
ill
earli
life
major
risk
factor
subsequ
asthma
develop
longitudin
analysi
shown
preschool
age
children
six
hrv
infect
per
year
winther
et
al
confirm
serial
viral
infect
lead
recurr
wheez
episod
jartti
et
al
led
hypothesi
recurr
hrv
infect
may
stimulu
asthma
develop
may
also
play
key
role
develop
continu
progress
airway
remodel
asthma
support
hypothesi
studi
use
cultur
human
airway
epitheli
cell
primari
site
viral
infect
airway
shown
hrv
infect
induc
epitheli
product
varieti
growth
factor
protein
link
remodel
process
airway
fig
includ
amphiregulin
member
epiderm
growth
factor
famili
activin
member
transform
growth
famili
leigh
et
al
protein
link
airway
subepitheli
fibrosi
asthma
enomoto
et
al
gregori
et
al
addit
hrv
infect
increas
epitheli
product
matrix
tacon
et
al
proteas
also
link
extracellular
matrix
turnov
airway
remodel
atkinson
senior
broid
well
vascular
endotheli
growth
factor
vegf
psarra
et
al
leigh
et
al
consid
primari
angiogen
factor
asthmat
airway
simcock
et
al
interestingli
vegf
level
also
increas
vivo
airway
line
fluid
natur
rhinoviru
infect
leigh
et
al
tacon
et
al
asthma
associ
impair
barrier
function
airway
epithelium
holgat
infect
sever
hrv
serotyp
shown
disrupt
barrier
function
lead
concomit
loss
junction
plaqu
protein
zona
cultur
polar
epitheli
cell
sajjan
et
al
contrast
other
fail
observ
loss
barrier
function
lopezsouza
et
al
increas
product
mucin
mucu
hypersecret
also
common
featur
airway
remodel
asthma
sever
studi
shown
hrv
infect
lead
increas
express
major
epitheli
mucin
inou
et
al
zhu
et
al
hewson
et
al
increas
epitheli
releas
also
detect
vivo
experiment
hrv
infect
hewson
et
al
induct
hrv
infect
epitheli
cell
link
activ
epiderm
growth
factor
receptor
well
activ
erk
mitogen
activ
protein
kinas
transcript
factor
zhu
et
al
hewson
et
al
taken
togeth
observ
support
concept
hrv
infect
may
key
trigger
airway
remodel
chang
young
children
develop
asthma
acut
exacerb
asthma
copd
cf
may
lifethreaten
major
caus
emerg
room
visit
hospit
account
total
cost
associ
diseas
repres
huge
health
care
burden
weiss
et
al
smith
et
al
pauwel
et
al
inde
total
cost
diseas
exce
billion
dollar
annual
unit
state
alon
upper
respiratori
viral
infect
major
risk
factor
associ
exacerb
asthma
copd
cf
van
ewijk
et
al
trave
proud
prospect
studi
shown
viral
pathogen
detect
acut
asthma
exacerb
children
adolesc
johnston
et
al
although
number
rna
virus
link
exacerb
asthma
hrv
domin
viral
pathogen
detect
viral
exacerb
johnston
et
al
khetsuriani
et
al
adult
viral
infect
detect
exacerb
hrv
common
viru
detect
nicholson
et
al
kistler
et
al
bacteri
viral
infect
major
trigger
etiolog
exacerb
copd
cf
wedzicha
donaldson
van
ewijk
et
al
studi
suggest
half
exacerb
copd
cf
associ
viral
infect
hrv
common
viral
pathogen
detect
greenberg
et
al
seemung
et
al
mcmanu
et
al
wat
et
al
exacerb
cf
copd
viral
infect
occur
either
alon
coinfect
bacteria
despit
strong
evid
link
respiratori
viral
infect
exacerb
lower
airway
diseas
mechan
respiratori
viru
infect
trigger
exacerb
fulli
understood
abil
multipl
respiratori
viru
speci
induc
exacerb
suggest
least
mechan
involv
common
rna
virus
link
diseas
exacerb
hrv
common
viru
link
lower
airway
exacerb
asthma
copd
cf
airway
epitheli
cell
primari
site
hrv
infect
although
infect
usual
begin
nasal
andor
orpharyng
airway
clear
evid
hrv
spread
lower
airway
epithelium
papadopoulo
et
al
mosser
et
al
contrast
virus
influenza
hrv
overtli
cytotox
airway
epitheli
cell
winther
et
al
subaust
et
al
impli
virusinduc
alter
epitheli
biolog
initi
develop
exacerb
suscept
individu
although
conceiv
case
virus
induc
cytotox
damag
may
contribut
diseas
sever
given
major
role
play
hrv
clinic
exacerb
howev
use
respons
induc
viru
prototyp
discuss
statu
lower
airway
diseas
may
regul
support
hypothesi
hrv
alter
epitheli
biolog
gene
array
analys
airway
epitheli
cell
obtain
either
vivo
hrv
infect
infect
cultur
epitheli
cell
confirm
alter
express
multipl
proinflammatori
cytokin
chemokin
also
rang
molecul
innat
antivir
host
defens
properti
proud
et
al
mrna
protein
analys
shown
hrv
infect
human
airway
epitheli
cell
induc
express
releas
broad
rang
growth
factor
includ
granulocyt
colonystimul
factor
gcsf
granulocytemacrophag
colonystimul
factor
gmcsf
could
regul
granulocyt
matur
surviv
activ
ii
pleiotrop
cytokin
includ
regul
sever
aspect
inflamm
iii
chemokin
includ
could
contribut
recruit
activ
sever
type
inflammatori
cell
airway
leigh
proud
moreov
mani
proinflammatori
molecul
also
increas
airway
secret
vivo
hrv
infect
leigh
proud
taken
togeth
increas
gener
chemokin
cytokin
would
expect
lead
recruit
activ
varieti
inflammatori
cell
type
within
airway
healthi
individu
reason
specul
base
respons
nasal
airway
viru
infect
lower
airway
epitheli
cell
would
trigger
modest
inflammatori
respons
airway
would
caus
lower
airway
diseas
overt
clinic
problem
vast
major
individu
contrast
individu
diseas
asthma
copd
cf
alreadi
preexist
lower
airway
inflamm
subject
particularli
inflamm
well
control
extra
inflammatori
burden
due
hrv
infect
may
suffici
caus
diseas
exacerb
addit
discuss
possibl
subject
lower
airway
releas
growth
factor
transform
growth
epiderm
growth
factor
egf
famili
could
contribut
remodel
via
regul
fibroblastmyofibroblast
releas
matrix
protein
lead
thicken
lamina
reticulari
matrix
may
regul
matrix
protein
turnov
vascular
endotheli
growth
factor
regul
angiogenesi
increas
releas
may
enhanc
mucu
product
inflammatori
diseas
may
also
level
impair
host
defens
could
also
lead
sever
virusinduc
inflammatori
respons
understand
mechan
virus
induc
epitheli
product
proinflammatori
cytokin
chemokin
may
permit
strategi
new
therapeut
intervent
case
hrv
known
molecul
induc
viru
render
replic
defici
suggest
viral
bind
receptor
suffici
induc
product
cytokin
sander
et
al
surpris
receptor
largest
group
hrv
famili
member
intercellular
adhes
receptor
neither
endogen
kinas
activ
known
kinas
recognit
site
greenwood
et
al
studi
shown
bind
hrv
lead
format
complex
cytoskelet
protein
ezrin
serv
linker
bind
spleen
tyrosin
kinas
syk
complex
appear
play
role
viru
intern
lau
et
al
syk
lead
activ
mitogen
activ
protein
kinas
kinas
trigger
downstream
cytokin
product
wang
et
al
src
tyrosin
kinas
also
associ
earli
link
hrv
signal
bentley
et
al
point
capac
direct
signal
hrv
receptor
trigger
epitheli
cytokin
product
unknown
although
earli
hrv
signal
may
contribut
inflammatori
respons
airway
unlik
signal
via
singl
viru
receptor
explain
abil
multipl
rna
virus
trigger
exacerb
lower
airway
diseas
major
cytokin
product
hrv
infect
epitheli
cell
appear
depend
upon
viral
intern
replic
indic
molecul
gener
viral
replic
necessari
cytokin
product
although
viru
specif
protein
rhinoviru
proteas
shown
modul
cell
function
exert
effect
nucleocytoplasm
transport
cleavag
transcript
factor
amineva
et
al
would
logic
assum
product
common
replic
multipl
virus
central
regul
inflammatori
respons
doublestrand
rna
dsrna
normal
present
eukaryot
cell
gener
replic
cycl
rna
virus
one
strand
use
templat
gener
new
genom
rna
consequ
dsrna
recogn
pattern
recognit
receptor
prr
pathogen
associ
molecular
pattern
pamp
number
prr
known
recogn
dsrna
first
prr
identifi
tolllik
receptor
tlr
alexopoul
et
al
although
initi
consid
essenti
recognit
viral
dsrna
subsequ
studi
show
mice
show
impair
pathogenesi
antivir
immun
number
virus
edelmann
et
al
suggest
prr
must
abl
recogn
dsrna
led
demonstr
member
dexdhbox
famili
cytoplasm
rna
helicas
fill
role
first
helicas
famili
member
link
viral
recognit
retino
acidinduc
genei
rigi
melanoma
differentiationassoci
gene
mda
yoneyama
et
al
kato
et
al
studi
show
viral
dsrna
differ
type
viru
differ
length
preferenti
recogn
two
prr
kato
et
al
takeuchi
akira
util
may
cell
type
specif
kato
et
al
recent
addit
member
dexdhbox
famili
cytoplasm
rna
helicas
includ
also
shown
sens
dsrna
least
dendrit
cell
zhang
et
al
lu
et
al
even
within
cell
type
specif
viru
hrv
controversi
regard
rel
role
tempor
use
rigi
mediat
dsrna
signal
slater
et
al
triantafil
et
al
hudi
et
al
grow
number
prr
potenti
recogn
dsrna
make
select
suitabl
target
therapeut
intervent
difficult
may
obviat
fact
prr
ultim
converg
common
downstream
activ
interferon
ifn
regulatori
factor
irf
regul
transcript
activ
multipl
proinflammatori
host
defens
gene
current
dogma
emphas
phosphoryl
activ
key
viral
host
defens
respons
nakhaei
et
al
may
prove
oversimplif
exampl
hrv
infect
actual
report
inhibit
activ
kotla
et
al
strongli
induc
activ
shown
play
key
role
induct
number
hrvinduc
gene
epitheli
cell
stirnweiss
et
al
zaheer
proud
consid
gener
proinflammatori
cytokin
chemokin
potenti
target
new
therapi
critic
know
molecul
contribut
diseas
pathogenesi
also
may
play
role
requisit
host
defens
one
potenti
clue
may
come
fact
hrv
infect
epitheli
cell
induc
gener
chemokin
cytokin
theori
recruit
multipl
cell
type
airway
hrv
infect
viral
exacerb
lower
airway
diseas
usual
associ
select
recruit
neutrophil
lymphocyt
airway
jarjour
et
al
inde
neutrophil
number
neutrophil
degranul
correl
diseas
sever
viral
exacerb
asthma
copd
wark
et
al
quint
wedzicha
thu
chemokin
recruit
activ
neutrophil
may
attract
target
addit
studi
select
recruit
neutrophil
also
suggest
may
mechan
recruit
cell
type
airway
select
regul
mechan
yet
well
defin
although
known
factor
present
airway
modul
epitheli
respons
hrv
infect
includ
cigarett
smoke
enhanc
hrvinduc
product
chemokin
chemotact
neutrophil
reduc
product
chemokin
link
recruit
eosinophil
natur
killer
cell
wiehler
proud
hudi
et
al
eddleston
et
al
hudi
proud
hudi
et
al
addit
abil
epitheli
cell
produc
proinflammatori
chemokin
cytokin
upon
hrv
infect
cell
also
regul
clinic
outcom
hrv
infect
directli
produc
molecul
antivir
host
defens
function
fig
gene
array
analys
human
airway
epitheli
cell
infect
either
vivo
vitro
hrv
shown
increas
express
wide
rang
gene
potenti
antivir
activ
proud
et
al
date
howev
gene
evalu
determin
gene
product
actual
abl
limit
hrv
infect
mani
gene
also
classifi
interferon
stimul
gene
isg
suggest
type
type
iii
interferon
ifn
play
key
role
regul
innat
immun
hrv
infect
inde
report
epitheli
product
andor
respons
hrv
infect
impair
patient
asthma
copd
suggest
contribut
suscept
hrvinduc
exacerb
diseas
wark
et
al
contoli
et
al
mallia
et
al
concept
impair
ifn
product
underli
viral
exacerb
lower
airway
diseas
howev
controversi
author
fail
observ
impair
ifn
respons
epitheli
cell
asthmat
compar
normal
subject
lopezsouza
et
al
bochkov
et
al
recent
data
author
report
origin
observ
suggest
ifn
defici
inher
featur
asthma
observ
featur
subject
asthma
whose
diseas
wellcontrol
syke
et
al
inde
number
investig
group
unabl
detect
measur
releas
type
ifn
protein
hrv
infect
epitheli
cell
despit
detect
induct
mrna
express
spurrel
et
al
khaitov
et
al
schneider
et
al
proud
et
al
bochkov
et
al
failur
detect
secret
type
ifn
protein
set
increas
express
panopli
isg
may
appear
paradox
howev
clear
preced
mani
isg
induc
independ
ifn
via
direct
activ
key
transcript
factor
number
virus
includ
hrv
spurrel
et
al
schmid
et
al
stirnweiss
et
al
proud
et
al
mention
signal
induc
dsrna
viral
replic
intermedi
induc
wide
rang
potenti
antivir
gene
although
mani
antivir
gene
product
assum
broad
specif
like
larg
number
antivir
gene
incorpor
capac
function
multipl
virus
well
redund
term
number
antivir
target
given
viru
despit
still
lack
knowledg
regard
antivir
pathway
critic
regul
respons
hrv
pathway
examin
date
hrv
well
known
induc
mark
express
member
synthetas
oa
famili
produc
atp
hovanessian
et
al
human
isoform
oa
encod
gene
induc
upon
hrv
infect
epitheli
cell
proud
et
al
welldefin
role
activ
rnase
l
silverman
rnase
l
dimer
express
potent
rnase
activ
therebi
degrad
singlestrand
rna
genom
rna
picornavirus
must
note
howev
picornavirus
defenseless
rnase
l
exampl
proteas
polioviru
homolog
hrv
potent
inhibitor
rnase
l
han
et
al
moreov
mice
defici
rnase
l
even
tripli
defici
rnase
l
rnadepend
protein
kinas
myxoviru
resist
still
abl
mount
signific
antivir
respons
picornavirus
encephalomyocard
viru
zhou
et
al
thu
pathway
must
also
play
role
antivir
defens
gene
array
analysi
human
airway
epitheli
gene
upregul
upon
hrv
infect
identifi
viperin
viru
inhibitori
protein
endoplasm
reticulum
associ
ifninduc
potenti
novel
antivir
viperin
known
interfer
replic
sever
virus
chin
cresswel
wang
et
al
zhang
et
al
use
sirna
knockdown
approach
confirm
viperin
also
compon
epitheli
antivir
defens
hrv
prevent
viperin
express
led
enhanc
replic
hrv
mechan
viperin
inhibit
replic
hrv
remain
unknown
identif
protein
radicalsadenosyllmethionin
enzym
rais
question
whether
enzym
activ
may
play
role
antivir
activ
shaveta
et
al
free
radic
nitric
oxid
known
play
role
host
defens
wide
rang
pathogen
proud
type
induc
nitric
oxid
synthas
ino
one
highli
induc
gene
airway
epitheli
cell
upon
experiment
hrv
infect
vitro
vivo
sander
et
al
proud
et
al
proud
et
al
epitheli
induct
ino
also
observ
upon
infect
virus
includ
rsv
influenza
uetani
et
al
kao
et
al
report
epitheli
ino
major
determin
level
exhal
lane
et
al
consist
increas
epitheli
express
ino
experiment
hrv
infect
vivo
correl
level
exhal
breath
subject
highest
level
exhal
lowest
symptom
experiment
hrv
infect
clear
viru
quickli
sander
et
al
data
support
fact
one
agent
suppress
replic
hrv
airway
epitheli
cell
well
inhibit
hrvinduc
product
number
cytokin
chemokin
independ
effect
viral
replic
sander
et
al
inhibit
hrvinduc
epitheli
chemokin
product
mediat
via
cgmpindepend
reduct
depend
transcript
pathway
koetzler
et
al
koetzler
et
al
also
known
inhibit
replic
respiratori
virus
includ
rsv
influenza
rimmelzwaan
et
al
aliahmad
et
al
thu
appear
gener
like
play
import
role
host
defens
infect
hrv
also
common
respiratori
virus
context
interest
note
epitheli
cell
subject
cf
patient
popul
poorli
respons
viral
infect
defici
abil
induc
ino
zheng
et
al
determin
potenti
antivir
agent
may
contribut
innat
antivir
defens
hrv
infect
could
identifi
addit
potenti
novel
therapeut
approach
regul
viral
exacerb
lower
airway
diseas
inhal
corticosteroid
ic
effect
therapi
control
asthma
use
primari
pharmacolog
treatment
recommend
nation
intern
asthma
manag
guidelin
patient
except
mild
intermitt
asthma
bateman
et
al
loughe
et
al
efficaci
ic
asthma
due
abil
suppress
allerg
inflamm
character
helper
type
driven
inflamm
airway
eosinophilia
loui
et
al
classic
inflammatori
profil
asthma
woodruff
et
al
corticosteroid
reduc
airway
express
number
chemokin
link
eosinophil
recruit
also
induc
eosinophil
apoptosi
cox
lead
reduc
eosinophil
inflamm
airway
djukanov
et
al
despit
overal
efficaci
ic
regardless
dose
adequ
control
asthma
signific
percentag
patient
moder
sever
asthma
includ
patient
smoke
smoke
attenu
respons
ic
thomson
et
al
lazaru
et
al
also
differ
inflammatori
profil
character
neutrophil
inflamm
barn
inde
airway
neutrophil
inflamm
gener
respond
poorli
ic
treatment
corticosteroid
actual
inhibit
neutrophil
apoptosi
cox
explain
efficaci
ic
minim
diseas
character
neutrophil
inflamm
cf
copd
copd
inhibitori
effect
smoke
limit
effect
ic
even
high
dose
reduc
sputum
neutrophil
level
patient
copd
keat
et
al
infect
respiratori
virus
includ
hrv
also
induc
inflamm
character
increas
neutrophil
neutrophil
number
neutrophil
degranul
correl
diseas
sever
viral
exacerb
copd
asthma
copd
wark
et
al
qiu
et
al
neither
topic
system
corticosteroid
significantli
reduc
symptom
experiment
hrv
infect
farr
et
al
gustafson
et
al
may
anticip
medic
may
limit
util
viral
exacerb
lower
airway
diseas
inde
ic
treatment
modul
lower
airway
inflammatori
respons
experiment
hrv
infect
grunberg
et
al
despit
util
corticosteroid
manag
diseas
exacerb
remain
controversi
part
may
role
corticosteroid
establish
better
control
underli
inflammatori
statu
usual
distinguish
effect
inflamm
trigger
exacerb
stimulu
addit
clinic
studi
rare
identifi
incit
stimulu
exacerb
inflammatori
phenotyp
prior
initi
treatment
case
asthma
observ
vari
age
subject
group
infant
preschool
children
major
episod
wheez
ill
attribut
viral
infect
popul
sever
month
ic
therapi
use
moder
dose
infant
young
children
recurr
episod
wheez
lead
improv
lung
function
symptom
compar
placebo
wilson
et
al
hofhui
et
al
moreov
although
oral
corticosteroid
recommend
sever
wheez
ill
preschool
children
major
evid
support
util
intervent
sever
studi
demonstr
system
corticosteroid
reduc
length
hospit
stay
symptom
sever
preschool
children
virusinduc
wheez
oommen
et
al
panick
et
al
beigelman
et
al
consist
observ
evid
corticosteroid
prevent
progress
episod
wheez
chronic
wheez
develop
asthma
inde
neither
chronic
administr
ic
two
year
intermitt
use
corticosteroid
wheez
episod
effect
prevent
develop
chronic
wheez
bisgaard
et
al
guilbert
et
al
awar
studi
specif
look
abil
corticosteroid
prevent
airway
remodel
failur
drug
prevent
asthma
develop
would
suggest
airway
remodel
also
unaffect
contrast
school
age
children
young
adult
allerg
asthma
domin
exacerb
induc
allergen
exposur
well
viral
infect
corticosteroid
clearli
efficaci
howev
patient
corticosteroid
may
benefit
unrel
effect
viral
inflamm
appropri
use
ic
provid
improv
control
diseas
patient
asthma
therebi
reduc
suscept
exacerb
trigger
varieti
stimuli
accord
evid
use
ic
earli
exacerb
reduc
admiss
row
et
al
gener
standard
care
acut
exacerb
school
age
children
adult
reli
use
short
cours
system
corticosteroid
ampl
evid
treatment
improv
symptom
reduc
admiss
reduc
risk
relaps
rachelefski
row
et
al
row
et
al
must
note
howev
studi
age
group
caus
effect
acut
exacerb
identifi
efficaci
corticosteroid
may
due
mainli
effect
allergendriven
eosinophil
type
exacerb
well
better
control
underli
chronic
allerg
inflamm
awar
studi
focus
exclus
virusinduc
exacerb
age
group
although
conflict
data
literatur
ic
usual
therapeut
level
tend
best
modest
effect
reduct
airway
remodel
jefferi
et
al
trigg
et
al
boulet
et
al
even
prolong
treatment
high
dose
ic
result
modest
reduct
reticular
basement
membran
thick
year
effect
tissu
collagen
stain
ward
et
al
patient
whose
asthma
suffici
control
inhal
corticosteroid
ic
guidelin
recommend
addit
inhal
longact
agonist
laba
combin
therapi
bateman
et
al
loughe
et
al
combin
icslaba
therapi
use
either
control
medic
laba
compon
rapid
onset
action
case
formoterol
controllerreliev
medic
treatment
regimen
shown
reduc
number
exacerb
experienc
asthma
patient
compar
appropri
control
treatment
pauwel
et
al
obyrn
et
al
scicchitano
et
al
obyrn
et
al
rabe
et
al
treatment
regim
also
associ
improv
asthma
control
exacerb
thu
unclear
much
reduct
exacerb
frequenc
observ
due
improv
underli
asthma
control
perhap
via
regul
inflammatori
respons
versu
reduct
respons
incit
stimuli
trigger
exacerb
studi
specif
examin
effect
treatment
virusinduc
exacerb
interestingli
recent
studi
allergeninduc
remodel
allergen
challeng
led
increas
number
myofibroblast
airway
although
treatment
inhal
corticosteroid
alon
reduc
allergeninduc
increas
myofibroblast
combin
corticosteroid
laba
significantli
reduc
myofibroblast
number
kelli
et
al
rais
intrigu
possibl
combin
therapi
may
prove
use
viru
induc
airway
remodel
thu
far
studi
test
possibl
patient
copd
sever
larg
observ
studi
suggest
ic
treatment
reduc
mortal
number
exacerb
copd
patient
sin
tu
soriano
et
al
presum
provid
improv
overal
diseas
control
contrast
subsequ
prospect
random
control
trial
fail
demonstr
signific
benefici
effect
ic
monotherapi
mortal
show
modest
reduct
exacerb
frequenc
vestbo
et
al
burg
et
al
calverley
et
al
argu
random
trial
may
fail
find
effect
due
small
sampl
size
rel
observ
studi
hand
also
argu
observ
studi
suffer
limit
assess
medic
use
may
suffer
immort
time
bia
attempt
resolv
issu
larg
prospect
studi
incorpor
timedepend
analysi
avoid
immort
time
bia
fan
et
al
studi
patient
receiv
medium
high
dose
inhal
corticosteroid
show
signific
reduct
exacerb
risk
contrast
sever
studi
report
oral
corticosteroid
benefici
treat
copd
exacerb
davi
et
al
niewoehn
et
al
aaron
et
al
wedzicha
donaldson
mechan
underli
benefici
effect
oral
corticosteroid
unclear
studi
effect
medic
copd
exacerb
known
viral
origin
use
combin
icslaba
standard
mainten
therapi
patient
moderatetosever
clinic
stabl
copd
larg
studi
treatment
regimen
combin
therapi
fail
achiev
statist
signific
reduc
caus
mortal
show
reduct
exacerb
frequenc
calverley
et
al
mechan
exacerb
frequenc
reduc
remain
unknown
potenti
role
leukotrien
receptor
antagonist
viral
exacerb
lower
airway
diseas
remain
controversi
report
level
sulfidopeptid
leukotrien
increas
infect
rsv
influenza
hrv
volovitz
et
al
gentil
et
al
although
data
latter
viru
remain
controversi
sever
studi
report
use
leukotrien
receptor
antagonist
normal
ad
secondlin
treatment
usual
ic
therapi
reduc
asthma
symptom
exacerb
due
cold
children
horiguchi
et
al
johnston
et
al
robertson
et
al
contrast
children
rsv
bronchiol
use
montelukast
reduc
symptom
significantli
effect
number
time
onset
subsequ
exacerb
bisgaard
et
al
proesman
et
al
moreov
experiment
hrv
infect
young
adult
asthma
treatment
montelukast
signific
effect
asthma
cold
symptom
viru
shed
kloepfer
et
al
thu
littl
evid
direct
effect
leukotrien
receptor
antagonist
pathogenesi
viru
infect
although
children
asthma
may
benefit
term
reduc
exacerb
frequenc
shortact
bronchodil
act
function
smooth
muscl
relax
essenti
maintain
airway
patenc
acut
exacerb
asthma
regardless
incit
trigger
howev
studi
directli
examin
effect
control
viral
exacerb
children
viral
bronchiol
agonist
affect
rate
durat
hospit
schindler
patel
et
al
inde
cochran
review
conclud
neither
adrenerg
agonist
anticholinerg
reduc
hospit
stay
wheez
children
year
age
insuffici
evid
support
uncrit
use
wheez
infant
chavass
et
al
everard
et
al
omalizumab
human
monoclon
antiig
antibodi
approv
treatment
moderatetosever
asthma
control
highdos
ic
icslaba
combin
therapi
humbert
et
al
studi
consist
shown
omalizumab
treatment
reduc
exacerb
rate
adult
children
moderatetosever
allerg
asthma
buss
et
al
soler
et
al
lanier
et
al
buss
et
al
omalizumab
also
improv
asthma
control
corticosteroidspar
given
omaluzimab
use
primarili
allerg
asthma
unclear
whether
omalizumab
reduc
exacerb
reduc
airway
inflamm
improv
diseas
control
djukanov
et
al
via
direct
effect
respons
exacerb
stimuli
patient
refractori
eosinophil
asthma
monoclon
antibodi
mepolizumab
shown
improv
diseas
control
reduc
exacerb
haldar
et
al
pavord
et
al
liu
et
al
ortega
et
al
treatment
use
almost
exclus
subject
eosinophil
inflamm
persist
despit
highdos
ic
oral
corticosteroid
therapi
function
via
reduc
inflammatori
respons
data
avail
abil
mepolizumab
impact
virusinduc
airway
inflamm
similarli
monoclon
antibodi
therapi
current
clinic
develop
includ
target
lebrikizumab
tralokinumab
pitrakinra
receptor
complex
therebi
inhibit
biolog
effect
dupilumab
yet
data
regard
efficaci
context
virallymedi
airway
inflamm
number
current
experiment
therapeut
approach
target
blockad
viral
attach
intern
andor
replic
focu
propos
modul
viral
pathogenesi
host
immun
respons
fig
vaccin
influenza
extrem
effect
reduc
infect
exacerb
lower
airway
diseas
induc
viru
howev
vaccin
avail
rsv
given
almost
serotyp
hrv
standard
vaccin
approach
feasibl
viru
although
palivizumab
human
monoclon
antibodi
avail
prophylact
treatment
rsv
cost
factor
led
use
limit
children
specif
predefin
condit
greatest
risk
sever
diseas
committe
ribavirin
shown
reduc
sever
rsv
bronchiol
administ
earli
diseas
onset
less
encourag
result
obtain
abil
ribavirin
treatment
reduc
subsequ
recurr
wheez
develop
asthma
examin
although
one
studi
report
reduct
respiratori
morbid
year
follow
edel
et
al
gener
reduct
asthma
develop
observ
longer
term
follow
kimpen
thu
addit
approach
treat
respiratori
viral
infect
sought
date
two
class
antivir
develop
treatment
influenza
infect
first
group
includ
rimantadin
amantadin
select
inhibitor
proton
channel
function
protein
influenza
drug
use
prophylact
prevent
infect
among
famili
member
index
case
galbraith
et
al
util
drug
limit
due
rapid
emerg
drug
resist
hayden
et
al
second
class
drug
neuraminidas
inhibitor
oral
administ
oseltamivir
inhal
zanamivir
neuraminidas
activ
influenza
essenti
viral
bud
prophylaxi
earli
treatment
either
oseltamivir
zanamivir
demonstr
signific
antivir
clinic
effect
hayden
et
al
although
sinc
widespread
emerg
influenza
viru
strain
resist
oseltamivir
resist
zanamivir
thu
far
remain
quit
infrequ
clinic
set
samson
et
al
sever
approach
taken
tri
limit
deleteri
clinic
effect
hrv
infect
first
prevent
viral
bind
receptor
hrv
member
classifi
three
genet
clade
hrva
hrvb
hrvc
base
upon
sequenc
homolog
particularli
coat
protein
palmenberg
et
al
approxim
strain
compris
hrva
hrvb
clade
term
receptor
usag
serotyp
hrva
gain
cellular
entri
via
member
lowdens
lipoprotein
receptor
famili
remain
serotyp
hrva
member
hrvb
use
infect
airway
epitheli
cell
greve
et
al
staunton
et
al
receptor
hrvc
clade
member
remain
identifi
treatment
inhal
recombin
solubl
experiment
hrv
infect
led
signific
reduct
symptom
sever
reduc
viral
shed
r
b
turner
et
al
although
studi
effect
establish
proof
principl
cost
dose
regimen
solubl
icam
use
studi
prove
impract
widespread
therapi
anoth
approach
prevent
hrv
entri
cell
develop
capsidbind
drug
bind
receptor
hrv
occur
bottom
deep
canyon
icosahedr
face
hrv
underneath
canyon
interior
hydrophob
pocket
form
betabarrel
vpi
capsid
protein
capsid
bind
drug
bind
within
pocket
result
inhibit
uncoat
strain
hrv
reduc
bind
receptor
smith
et
al
pevear
et
al
administr
novel
oral
absorb
capsidbind
drug
pleconaril
begin
within
h
symptom
develop
shown
reduc
symptom
durat
sever
naturallyacquir
hrv
infect
concern
regard
effect
cytochrom
howev
preclud
clinic
develop
oral
antivir
treatment
drug
subsequ
reformul
nasal
spray
report
clinicaltrialsgov
random
multicent
doubleblind
placebocontrol
trial
effect
cold
symptom
asthma
exacerb
complet
result
studi
yet
report
among
compon
hrv
genom
proteas
essenti
cleavag
viral
polyprotein
thu
replic
led
develop
inhibitor
hrv
proteas
therapi
reduc
viral
replic
multipl
intranas
administr
one
compound
ruprintrivir
significantli
inhibit
symptom
viral
load
experiment
hrv
infect
even
administ
begin
h
infect
sinc
report
howev
ruprintrivir
significantli
reduc
symptom
viral
load
subsequ
natur
infect
studi
clinic
develop
pursu
although
primari
data
present
patick
et
al
inhibitor
proteas
never
evalu
abil
limit
hrv
induc
exacerb
lower
airway
diseas
given
challeng
develop
drug
inhibit
hrv
infect
andor
replic
altern
consider
could
includ
attempt
modul
aspect
viral
pathogenesi
exacerb
lower
airway
diseas
view
relationship
neutrophil
recruitmentactiv
viral
exacerb
lower
airway
diseas
feasibl
antagonist
may
use
limit
symptom
although
sever
antagonist
alreadi
exist
knowledg
examin
hrv
infect
moreov
concern
regard
potenti
caus
deleteri
offtarget
viral
replic
signal
downstream
pattern
recognit
receptor
releas
bind
specif
proinflammatori
mediat
supplement
interferon
specif
isg
modul
specif
antivir
immun
respons
abbrevi
hrv
human
rhinoviru
intercellular
adhes
dsrna
doublestrand
rna
tolllik
receptor
retino
acid
induc
genei
melanoma
differentiationassoci
trif
tirdomaincontain
adapterinduc
receptor
interact
promot
stimul
tnf
receptorassoci
fadd
fasassoci
protein
death
domain
irf
interferon
regulatori
factor
nuclear
factor
kappalightchainenhanc
activ
b
cell
isg
interferonstimul
gene
effect
via
impair
neutrophil
function
concern
prove
valid
would
neg
impact
develop
less
clear
aspect
viral
inflamm
target
inhibit
proinflammatori
respons
observ
may
also
contribut
innat
immun
continu
gain
greater
insight
mechan
viral
infect
exacerb
inflamm
possibl
select
inhibit
key
virusspecif
signal
could
target
one
potenti
approach
enhanc
innat
antivir
immun
respons
mention
suggest
patient
asthma
copd
impair
type
ifn
product
upon
hrv
infect
remain
controversi
import
role
ifn
antivir
immun
well
establish
concept
administ
type
ifn
reduc
symptom
hrv
infect
new
sever
studi
show
either
prevent
hrv
infect
prophylact
administr
modestli
reduc
cold
symptom
administ
soon
infect
hayden
gwaltney
hayden
et
al
higgin
et
al
earli
studi
use
high
dose
ifn
associ
nasal
bleed
patient
transient
leukopenia
hayden
gwaltney
conclud
type
ifn
would
use
treatment
hrvinduc
cold
given
modest
efficaci
rel
cost
side
effect
profil
none
earli
studi
howev
extend
look
exacerb
lower
airway
diseas
trigger
viral
infect
recent
studi
examin
question
use
dose
much
lower
use
earli
cold
studi
shown
induc
marker
ifn
antivir
activ
airway
studi
examin
asthma
subject
histori
exacerb
link
viral
infect
administ
day
begin
h
onset
cold
symptom
primari
outcom
asthma
symptom
assess
valid
asthma
control
questionnair
signific
effect
treatment
observ
primari
endpoint
although
modest
chang
seen
sever
secondari
outcom
interest
djukanov
et
al
although
result
disappoint
preclud
concept
enhanc
host
innat
immun
hrv
potenti
treatment
approach
inde
controversi
whether
type
ifn
necessari
mediat
epitheli
antivir
respons
hrv
although
detect
type
ifn
mrna
almost
univers
observ
hrv
infect
epitheli
cell
sever
investig
fail
detect
releas
protein
spurrel
et
al
khaitov
et
al
schneider
et
al
proud
et
al
inde
report
hrv
infect
actual
suppress
type
ifn
induct
kotla
et
al
also
ampl
preced
viral
induct
isg
absenc
function
ifn
respons
via
direct
viral
activ
key
transcript
factor
schmid
et
al
moreov
broad
panopli
isg
induc
upon
viral
infect
like
select
group
gene
may
import
regul
specif
virus
thu
target
approach
enhanc
endogen
product
exogen
supplement
specif
molecul
demonstr
antivir
activ
key
respiratori
virus
may
promis
therapeut
approach
exampl
given
evid
inhibit
replic
respiratori
virus
includ
hrv
influenza
rsv
well
reduc
proinflammatori
chemokin
product
topic
administr
nitric
oxid
donor
may
provid
potenti
approach
limit
viru
induc
inflamm
continu
gain
greater
insight
mechan
viral
infect
enhanc
product
specif
proinflammatori
cytokin
endogen
mechan
host
defens
altern
target
therapeut
strategi
also
may
deriv
dr
leigh
consult
almiral
astrazeneca
forest
glaxosmithklin
receiv
research
support
amgen
astrazeneca
genentech
glaxosmithklin
novarti
ono
pharma
teva
pharmaceut
industri
money
institut
also
receiv
speaker
fee
almiral
astrazeneca
forest
glaxosmithklin
novarti
dr
proud
serv
consult
janssen
pfizer
receiv
research
support
astrazeneca
medimmun
money
institut
